New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 23, 2016 – The FDA announced the discontinuation of Vibativ (telavancin) 250 mg vials due to business reasons.
Download PDF
Return to publications
